This multicentre study, with a randomised controlled repeated measures experimental design, will be conducted in several Portuguese institutions, which provide care and supportive services for older adults diagnosed with mild or moderate Alzheimer's disease (AD), with an aim to assess the effect of individual cognitive stimulation (CS) on memory and executive functioning. Participants in the intervention group will attend 24 individual CS sessions, twice weekly for 12 weeks. Participants in the control group will complete their usual routines without any activity restrictions.
Age range
65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Cognitive functioning assessed through Mini-Mental State Examination (MMSE)
Timeframe: baseline
Change in cognitive functioning assessed through Mini-Mental State Examination (MMSE)
Timeframe: 12 weeks after the beginning of the intervention
Change in cognitive functioning assessed through Mini-Mental State Examination (MMSE)
Timeframe: 12 weeks after end of intervention
Cognitive functioning assessed through Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-COG)
Timeframe: baseline
Change in cognitive functioning assessed through Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-COG)
Timeframe: 12 weeks after the beginning of the intervention
Change in cognitive functioning assessed through Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-COG)
Timeframe: 12 weeks after end of intervention
Memory function evaluated through Memory Alteration Test (MAT)
Timeframe: baseline
Change in memory function evaluated through Memory Alteration Test (MAT)
Timeframe: 12 weeks after the beginning of the intervention
Change in memory function evaluated through Memory Alteration Test (MAT)
Timeframe: 12 weeks after end of intervention
Memory function evaluated through Free and Cued Selective Reminding Test (FCSRT)
Timeframe: baseline
Change in memory function evaluated through Free and Cued Selective Reminding Test (FCSRT)
Timeframe: 12 weeks after the beginning of the intervention
Change in memory function evaluated through Free and Cued Selective Reminding Test (FCSRT)
Timeframe: 12 weeks after end of intervention
Executive functions assessed through Frontal Assessment Battery (FAB)
Timeframe: baseline
Change in executive functions assessed through Frontal Assessment Battery (FAB)
Timeframe: 12 weeks after the beginning of the intervention
Change in executive functions assessed through Frontal Assessment Battery (FAB)
Timeframe: 12 weeks after end of intervention
Executive functions assessed through Trail Making Test (TMT)
Timeframe: baseline
Change in executive functions assessed through Trail Making Test (TMT)
Timeframe: 12 weeks after the beginning of the intervention
Change in executive functions assessed through Trail Making Test (TMT)
Timeframe: 12 weeks after end of intervention